Article Contents ::
- 1 Details About Generic Salt :: Miconazo
- 2 Main Medicine Class:: Anti-infective,antifungal
- 3 (my-KAHN-uh-zole) Absorbine Antifungal Foot Powder Class: Anti-infective/antifungal
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Miconazo
Main Medicine Class:: Anti-infective,antifungal
(my-KAHN-uh-zole)
Absorbine Antifungal Foot Powder
Class: Anti-infective/antifungal
Drugs Class ::
Action Alters permeability of fungal cell membrane, leading to cell death.
Indications for Drugs ::
Indications Parenteral form: Treatment of severe systemic fungal infections. Vaginal form: Local treatment of vulvovaginal candidiasis (moniliasis). Topical form: Treatment of topical fungal infections, including tinea infections and candidiasis.
Drug Dose ::
Route/Dosage
Systemic Infections
ADULTS: IV 200–3600 mg/day. May divide into 3 doses. Treatment of meningitis is supplemented by intrathecal injections of 20 mg/dose. Treatment of bladder infections is supplemented by bladder instillations of 200 mg per dose. CHILDREN 1–12 YR: IV 20–40 mg/kg/day (maximum 15 mg/kg/dose). CHILDREN < 1 YR: IV 15–30 mg/kg/day (maximum 15 mg/kg/dose).
Vaginal Infections
ADULTS: Intravaginal 1 suppository (200 mg) at bedtime for 3 days or 1 suppository (100 mg) for 7 days or 1 applicatorful at bedtime for 7 days.
Topical Infections
ADULTS: Topical Apply to infected area bid.
Contraindication ::
Contraindications Hypersensitivity to imidazoles.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy in children < 1 yr not studied sufficiently. Cardiac effects: Have occurred, possibly because of too-rapid administration. Cremophor-type vehicle: Present in IV formulation; may cause electrophoretic abnormalities of lipoprotein; usually reversible.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Tachycardia; arrhythmia; cardiorespiratory arrest. DERM: Phlebitis at infusion site; pruritus; rash; skin irritation, sensitization and burning from topical preparations. GI: Nausea; vomiting; diarrhea; anorexia. HEMA: Transient decreases in hematocrit; thrombocytopenia. META: Hyperlipemia possibly caused by vehicle. OTHER: Anaphylaxis; fever; chills. Topical or vaginal forms may cause similar reactions.
Drug Mode of Action ::
Action Alters permeability of fungal cell membrane, leading to cell death.
Drug Interactions ::
Interactions
Anticoagulants, oral: May cause increased anticoagulant effect. Antihistamines, nonsedating type (eg, astemizole, terfenadine): Cardiotoxicity, including arrhythmias and death, has occurred when agents of this type were used together with azole-type antifungals.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Note history of blood dyscrasias and hyperlipidemia.
- Monitor hemoglobin, hematocrit, electrolytes and lipids.
- Avoid having topical products come into contact with eyes.
- Refrigerate suppositories.
Drug Storage/Management ::
Administration/Storage
- Dilute IV admixture in 200 ml of 0.9% Sodium Chloride Injection or D5W. Infuse at rate of 2 hr/amp.
- Continue treatment until clinical and lab tests indicate absence of fungal infection.
- Topical lotion is preferred in intertriginous areas. If cream is used, use sparingly to avoid maceration effects.
- Spray or sprinkle powder liberally over affected area bid.
Drug Notes ::
Patient/Family Education
- With topical therapy, instruct patient to use for full treatment time, even if symptoms improve. Advise patient to notify physician if there is no improvement in 2 wk.
- With topical therapy, if condition worsens or if burning, itching or redness occurs, instruct patient to discontinue use and notify physician.
- With vaginal therapy, instruct patient to refrain from sexual intercourse or to have partner use condom for protection and to prevent reinfection. Advise patient to apply medication at bedtime.
- Suggest patient use sanitary pad to prevent staining of clothing.
- With vaginal therapy, instruct patient not to discontinue use during menstruation.